Patients suffering from lupus, an autoimmune disease that frequently causes joint pain, tried experimental CAR T-cell therapy, which greatly alleviated their symptoms. A recent study in the New ...
A phase I study of a next-generation CAR T cell therapy showed a 52 percent complete remission rate for patients with relapsed/refractory lymphoma. A next-generation "armored" CAR T cell therapy ...
CAR-T is a powerful tool which is still evolving. Here we highlight what is new in CAR-T cell therapy Cancer cells often play hide-and-seek with the immune system in an attempt to evade catastrophic ...
To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Dr. Melhem Solh, medical director of the cellular therapy ...
CAR-T cell therapy faces accessibility challenges, primarily available at large urban centers, leading to geographic and socioeconomic disparities. The KarMMa-3 study showed Abecma CAR-T therapy ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results